ATE365210T1 - Glykosylierte proteine mit reduzierter allergenität - Google Patents

Glykosylierte proteine mit reduzierter allergenität

Info

Publication number
ATE365210T1
ATE365210T1 AT99947259T AT99947259T ATE365210T1 AT E365210 T1 ATE365210 T1 AT E365210T1 AT 99947259 T AT99947259 T AT 99947259T AT 99947259 T AT99947259 T AT 99947259T AT E365210 T1 ATE365210 T1 AT E365210T1
Authority
AT
Austria
Prior art keywords
allergenity
reduced
glycosylated proteins
proteins
allergenicity
Prior art date
Application number
AT99947259T
Other languages
English (en)
Inventor
Arne Olsen
Erwin Roggen
Steffen Ernst
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As filed Critical Novozymes As
Application granted granted Critical
Publication of ATE365210T1 publication Critical patent/ATE365210T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT99947259T 1998-10-30 1999-10-12 Glykosylierte proteine mit reduzierter allergenität ATE365210T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199801401 1998-10-30
DKPA199801551 1998-11-25
DKPA199900682 1999-05-17
DKPA199901419 1999-10-04

Publications (1)

Publication Number Publication Date
ATE365210T1 true ATE365210T1 (de) 2007-07-15

Family

ID=27439358

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99947259T ATE365210T1 (de) 1998-10-30 1999-10-12 Glykosylierte proteine mit reduzierter allergenität

Country Status (9)

Country Link
EP (1) EP1124946B1 (de)
JP (1) JP2002531067A (de)
CN (1) CN1325443A (de)
AT (1) ATE365210T1 (de)
AU (1) AU774156B2 (de)
CA (1) CA2348822A1 (de)
DE (1) DE69936351T2 (de)
ES (1) ES2289824T3 (de)
WO (1) WO2000026354A1 (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AU2003203147B2 (en) 1998-03-23 2008-05-29 Novozymes A/S Phytase variants
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
BR0207576A (pt) 2001-02-27 2004-04-27 Maxygen Aps Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP1463751B1 (de) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albuminfusionsproteine
SI1499719T1 (sl) 2002-04-30 2011-03-31 Bayer Healthcare Llc Polipeptidne variante faktorja VII ali VIIa
US7943763B2 (en) * 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
ATE494368T1 (de) 2002-10-01 2011-01-15 Novozymes As Polypeptide der gh-61-familie
JP2006523211A (ja) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
DK2085470T3 (da) 2003-03-20 2012-08-06 Bayer Healthcare Llc FVII- eller FVIIa-varianter
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP2338333B1 (de) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylierungsverfahren und durch die Verfahren hergestellte Proteine/Peptide
WO2004103275A2 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
CN1839203B (zh) 2003-06-19 2011-11-16 拜耳医药保健有限公司 因子VII或VIIa的GLA结构域变体
WO2004111224A1 (en) 2003-06-19 2004-12-23 Novozymes A/S Improved proteases and methods for producing them
EP1639106B1 (de) 2003-06-19 2010-05-26 Novozymes A/S Proteasen
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
BRPI0414959A (pt) 2003-10-10 2006-11-07 Novozymes As variante de uma protease precursora, sequência de ácido nucleico isolado, construção de ácido nucleico, vetor de expressão e célula hospedeira recombinantes, métodos para produzir a variante de protease, para melhorar o valor nutricional de uma ração animal, e para tratar proteìnas, planta transgênica, ou parte da planta, animal transgênico, não humano, ou produtos, ou elementos deste, aditivo e composição de ração animal, uso da variante de protease e/ou da composição, protease, e, estrutura 3d
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1709165B1 (de) 2004-01-06 2014-04-23 Novozymes A/S Polypeptide von alicyclobacillus
ES2560657T3 (es) 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
US20060148680A1 (en) 2004-01-14 2006-07-06 Kieliszewski Marcia J Glycoproteins produced in plants and methods of their use
JP2007519422A (ja) 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
EP1751177A4 (de) 2004-04-19 2008-07-16 Univ Ohio Vernetzbare glycoproteine und verfahren zu ihrer herstellung
US20070225207A1 (en) * 2004-04-23 2007-09-27 Novozymes A/S Group 1 Mite Polypeptide Variants
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
JP5623691B2 (ja) 2004-06-21 2014-11-12 ノボザイムスアクティーゼルスカブ プロテアーゼ
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1799249A2 (de) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
AR050895A1 (es) 2004-10-04 2006-11-29 Novozymes As Polipeptidos que tienen actividad de fitasa y polinucleotidos que los codifican
ES2614744T3 (es) 2004-10-04 2017-06-01 Novozymes A/S Polipéptidos con actividad de fitasa y polinucleótidos que codifican los mismos
SI2586456T1 (sl) 2004-10-29 2016-05-31 Ratiopharm Gmbh Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF)
AU2005322019B2 (en) 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
ATE541934T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
SG161210A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
EP1858543B1 (de) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylierten Granulocyten-Kolonie-stimulierender Faktor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2975135A1 (de) 2005-05-25 2016-01-20 Novo Nordisk A/S Glykopegylierter Faktor IX
KR20080026135A (ko) 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
US8119387B2 (en) 2005-08-16 2012-02-21 Novozymes A/S Polypeptides of strain Bacillus sp. P203
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP2339014B1 (de) 2005-11-16 2015-05-27 Ambrx, Inc. Verfahren und Zusammensetzungen mit nichtnatürlichen Aminosäuren
EP1998793A1 (de) 2006-03-22 2008-12-10 Novozymes A/S Verwendung von polypeptiden mit antimikrobieller wirkung
ES2531434T3 (es) 2006-04-04 2015-03-16 Novozymes A/S Variantes de fitasa
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
EP2069396B1 (de) 2006-09-08 2015-10-21 Ambrx, Inc. Modifiziertes polypeptid oder fc-gerüste aus humanem plasma und ihre verwendung
EP2054521A4 (de) 2006-10-03 2012-12-19 Novo Nordisk As Verfahren zur reinigung von polypeptid-konjugate
MX2009006597A (es) 2006-12-21 2009-07-02 Novozymes As Variantes de lipasa para uso farmaceutico.
US8221743B2 (en) 2006-12-22 2012-07-17 Novozymes A/S Use of polypeptides against diseases caused by protozoans
DK2129781T3 (da) 2007-03-26 2014-03-31 Novozymes As Hafnia-phytase
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
ES2406267T3 (es) 2007-04-03 2013-06-06 Biogenerix Ag Métodos de tratamiento usando G-CSF glicopegilado
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
NZ591235A (en) 2008-07-23 2012-07-27 Ambrx Inc Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
TR201802361T4 (tr) 2008-09-26 2018-03-21 Ambrx Inc Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
ES2544645T3 (es) 2008-09-26 2015-09-02 Novozymes A/S Variantes de fitasa de Hafnia
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
ES2585284T3 (es) * 2010-03-30 2016-10-04 Novozymes A/S Métodos para el aumento de productos derivados de procesos de fermentación
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
MY162837A (en) 2010-08-17 2017-07-31 Ambrx Inc Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
JP5808559B2 (ja) 2011-03-31 2015-11-10 独立行政法人石油天然ガス・金属鉱物資源機構 炭化水素油の製造方法、フィッシャー・トロプシュ合成反応装置及び炭化水素油の製造システム
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
EP3370771A4 (de) 2015-11-03 2019-06-19 Ambrx, Inc. Anti-cd3-folat-konjugate und deren verwendungen
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
AU2018329850A1 (en) 2017-09-08 2020-04-23 Bristol-Myers Squibb Company Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH)
WO2020010117A2 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf21 formulations
SG11202101875VA (en) 2018-08-28 2021-03-30 Ambrx Inc Anti-cd3 antibody folate bioconjugates and their uses
JP2022506649A (ja) 2018-11-05 2022-01-17 ブリストル－マイヤーズ スクイブ カンパニー Ｐｅｇ化タンパク質の精製方法
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
EP4196575A1 (de) 2020-08-13 2023-06-21 Novozymes A/S Phytasevarianten und polynukleotide zur codierung davon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621118D0 (en) * 1986-09-01 1986-10-08 Whitbread & Co Plc Stabilised polypeptides
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
GB9517494D0 (en) * 1995-08-25 1995-10-25 Mini Agriculture & Fisheries Recominent DNA expression system

Also Published As

Publication number Publication date
CA2348822A1 (en) 2000-05-11
DE69936351T2 (de) 2008-02-21
EP1124946B1 (de) 2007-06-20
ES2289824T3 (es) 2008-02-01
WO2000026354A1 (en) 2000-05-11
AU6078699A (en) 2000-05-22
CN1325443A (zh) 2001-12-05
DE69936351D1 (de) 2007-08-02
JP2002531067A (ja) 2002-09-24
AU774156B2 (en) 2004-06-17
EP1124946A1 (de) 2001-08-22

Similar Documents

Publication Publication Date Title
ATE365210T1 (de) Glykosylierte proteine mit reduzierter allergenität
NO2017027I1 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
EP1423510A4 (de) Antikörperglykosylierungsvarianten mit erhöhter antikörperabhängiger zellulärer zytotoxizität
BR0215405A (pt) Composições e processos de uso de collajolie
MXPA03007323A (es) Proteinas artificiales con inmunogenicidad reducida.
ATE347057T1 (de) Federelement
BR0204884B1 (pt) montagem de coxim de cisalhamento.
AU2001282399A1 (en) Resorcinol derivatives
ATE330017T1 (de) Kallikrein gen
BR0201919B1 (pt) colheitadeira.
CA97633S (en) Trimmer
ITRM20010044A0 (it) Integratore alimentare ad effetto dimagrante.
WO2002010752A3 (de) Sensor-chips mit polysiloxan-mehrfachschichten
BR0214423B1 (pt) correia de baixo módulo.
AU2001291532A1 (en) Lighting device
MY141606A (en) N-alkoxyalkyl-substituted benzimidazoles, their preparation and their use as agents against parasitic protozoa
DE50110117D1 (de) Lineare Polydialkylorganosiloxane mit Polyoxyalkylen- und aminofunktionellen Gruppen, die zusätzlich endständige Alkoxygruppen aufweisen
AU2003259750A1 (en) Methods and compositions for targeting secretory lysosomes
ES2192034T3 (es) Feniluracilos substituidos con efecto herbicida.
BR0315222A (pt) Promotor de il-18bp, sua preparação e uso
ITMI20021205A1 (it) Uso di proteine per il trattamento della leishmaniosi
ITMI20022028A1 (it) Fenton i.s.
DE60117001D1 (de) Nectin-3 proteine
MY142798A (en) Methods for preventing glyconoylation of proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties